OncoCyte reports Medicare boosts reimbursement for GraftAssureCore

On May 19, Oncocyte (OCX) provided “a positive update on pricing” for its next-generation lab-developed test, GraftAssureCore. The Centers for Medicare & Medicaid Services has improved its reimbursement rate to $2,753 per result. This represents an increase from the prior structure using an earlier version of the assay, which paid $2,222 for first-time testing of a patient and $1,029 for subsequent tests, noted the company. GraftAssureCore is Oncocyte’s lab-developed test, which is run at the company’s CLIA-certified Nashville lab. “Over the past two years Oncocyte has made significant investments in improving the scalability and manufacturability of our workflow to support our kitted test program. Last fall, we transferred these improvements into our CLIA lab and submitted to MolDX3 for repricing. We are very pleased with the result,” said CEO Josh Riggs.